¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20
±³À°ÀÏÀÚ : 2022-05-20
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ(¼Ò°øµ¿)  
±³À°ÁÖÁ¦ : (ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : meetings@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú¾à¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï- ȸ¿ø : 40,000, ÁØȸ¿ø : 30,000, 65¼¼ ÀÌ»ó : ¹«·á -ºñȸ¿ø ±³¼ö, Àü¹®ÀÇ ¹Ú»ç±Þ ¿¬±¸¿ø : 50,000ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 30,000ÇöÀåµî·Ï- ȸ¿ø : 60,000, ÁØȸ¿ø :50,000, 65¼¼ ÀÌ»ó : ¹«·á - ºñȸ¿ø±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø : 70,000ÀüÀÓÀÇ,Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 50,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:00~09:40 Cost and value in cancer care  Leonard Saltz(MSKCC) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:40~10:00 One step back to move forward for KSMO  ±èÅ¿ø(¼­¿ï¾Æ»êº´¿ø) 
±âŸ 05-20 Crystal Ballroom A (2F) 10:00~10:10 KSMO ¹Ì¼Ç/ºñÀü/Çٽɰ¡Ä¡ ¼±Æ÷½Ä  () 
È޽Ġ05-20 Crystal Ballroom A (2F) 10:10~10:20 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:20~10:35 Progress in precision oncology : KPMNG report  ±èÅ¿ë(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:35~10:55 Challenges to harmonize Molecular Tumor Board decision – case sharing from KOSMOS study   À̼¼ÈÆ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:55~11:10 Implementing NGS and MTB guideline in clinical practice  À±½Å±³(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:10~11:30 Lessons learned from Precision oncology clinical trials and suggestions for the future studies   ÃÖÀ±Áö(°í´ë¾È¾Ïº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 11:30~11:40 Discussion  () 
È޽Ġ05-20 Crystal Ballroom A (2F) 11:40~11:50 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:50~12:30 ±è³ë°æ»ó ½Ã»ó ¹× °­¿¬  ±è¿­È«(°í´ë¾È¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 12:30~13:10 Rozlytrek: Leading a new era in Personalized Healthcare  Á¶º´Ã¶(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:10~13:25 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ¾Ï ´ÙÇÐÁ¦ Á¦µµ  È²ÀαÔ(Á߾Ӵ뺴¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:25~13:35 Discussion  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:35~13:50 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÀûÁ¤¼º Æò°¡ Á¦µµ  °íÀ±È£(ÀºÆò¼º¸ðº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:50~14:00 Discussion  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:00~14:15 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÁöºÒÁ¦µµ  Á¤ÁÖ¿µ(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:15~14:25 Discussion  () 
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:25~14:30 ÁÂÀå Á¤¸® ÅäÀÇ  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:30~14:40 2021³â º¸ÇèÁ¤Ã¥¿¬±¸ºñ»ó ¿¬±¸ ¹ßÇ¥  ¿ø¿µ¿õ(ÇѾç´ë±¸¸®º´¿ø) 
È޽Ġ05-20 Crystal Ballroom A (2F) 14:40~14:50 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:50~15:10 Identification of Resistance Mechanisms: Immune Checkpoint Therapy  ¹ÚÁöÇö(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:10~15:30 Single cell genomics approach to identify immune determinants for PD-1 inhibitors  ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:30~15:50 T cell Exhaustion and Relevance for Immunotherapy of Cancer:  ¹Ú¼öÇü(KAIST) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:50~16:10 The Evolving Landscape of Immunotherapy  ÀÌ´ëÈ£(¼­¿ï¾Æ»êº´¿ø) 
È޽Ġ05-20 Crystal Ballroom A (2F) 16:10~16:20 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 16:20~17:00 Circulating tumor DNA to direct therapy for cancer  Nicholas turner(The Institute of Cancer Research) 
±âŸ 05-20 Crystal Ballroom A (2F) 17:00~17:30 Á¤±âÃÑȸ & Awards  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѳ»½Ã°æ³ú¼ö¼úÇÐȸ Á¦6ȸ Á¤±âÇмú´ëȸ : 2022-05-20
´ÙÀ½±Û Á¦50Â÷ ´ëÇѼҾƳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ : 2022-05-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
240 ¼­¿ï ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ International Colorectal Research Summit 2018 : 2018-09-09 0 468 2018-07-28
239 ºÎ»ê µ¿¾Æ´ëÇб³ÀÇ·á¿ø Á¦ 1ȸ µ¿¾Æ´ëÇб³ Á¤Çü¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-09 0 1,154 2018-07-28
238 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018 SNU Orthopaedic Update(III) Foot & Ankle : 2018-09-09 0 936 2018-07-28
237 ºÎ»ê ¼¼ºê¶õ½ºº´¿ø 70Â÷ fresh cadaver shoulder arthroscopy workshop : 2018-09-09 0 456 2018-07-28
236 ºÎ»ê ´ëÇѽÅÀåÇÐȸ ºÎ¿ï°æ Ç÷¾×Åõ¼® ½ÉÆ÷Áö¾ö : 2018-09-09 0 1,224 2018-07-28
235 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø °íÀ§Çè »ê¸ð/½Å»ý¾ÆÀÇ Ã³Ä¡ ¹× °£È£ : 2018-09-09 0 461 2018-07-28
234 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¼¼ºê¶õ½º ¾È°ú 133Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2018-09-09 0 625 2018-07-28
233 °æ±â ¼øõÇâ´ëÇб³ºÎõº´¿ø ³»½Ã°æ ÃÊÀ½ÆÄ ¶óÀÌºê ½ÉÆ÷Áö¾ö 2018 : 2018-09-09 0 979 2018-07-28
232 ¼­¿ï 2018 ´ëÇѹ̿뼺Çü·¹ÀÌÀúÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-09 0 3,290 2018-07-28
231 ¼­¿ï Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-09 0 864 2018-07-28
230 ¼­¿ï ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú Áö¿ªÀÇ»ç °£´ãȸ : 2018-09-08 0 687 2018-07-28
229 Á¦ÁÖ ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ CAMP(Chronic Airway Management in Pulmonary disease) ½ÉÆ÷Áö¾ö : 2018-09-08 0 634 2018-07-28
228 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/08 : 2018-09-08 0 611 2018-07-28
227 ¼­¿ï 2018³â À»Áö´ëÇб³ À»Áöº´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-08 0 1,203 2018-07-28
226 ¼­¿ï 2018³â ´ëÇѳëÀθ¶ÃëÅëÁõÇÐȸ Çмú´ëȸ : 2018-09-08 0 579 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷